To Amend The Abortion-inducing Drugs Safety Act To Increase The Criminal Penalties And Clarify The Civil Penalties.
HB1678 amends Arkansas’s Abortion-Inducing Drugs Safety Act to substantially increase penalties for violations involving abortion-inducing drugs. The bill changes the general criminal penalty for intentionally, knowingly, or recklessly violating the subchapter from a Class A misdemeanor to a Class D felony. It also adds a new felony penalty and a $50,000 fine per violation for licensed healthcare providers, pharmacists, or other individuals or entities that prescribe, authorize, or approve the sale or delivery of abortion-inducing drugs in violation of the law.
The bill also expands and clarifies civil remedies. It states that violations may support malpractice claims, professional discipline, and wrongful-death recovery, and it expressly allows the woman, the father of the unborn child, certain family members, prosecutors, or the Attorney General to seek injunctive relief against violators. It further classifies violations as deceptive and unconscionable trade practices under the Deceptive Trade Practices Act, bars civil liability against the pregnant woman, permits anonymity protections for plaintiffs, authorizes attorney’s fees for prevailing parties, and requires revocation of a physician’s license upon a Medical Board finding of noncompliance.
If enacted, HB1678 would tighten Arkansas law governing abortion-inducing drugs by elevating criminal exposure, adding a specific felony-and-fine provision for medical professionals and related actors, and broadening the civil enforcement framework. It would affect licensed healthcare providers, pharmacists, entities involved in dispensing or approving abortion-inducing drugs, the Arkansas State Medical Board, and potential private and public plaintiffs by creating additional causes of action and enforcement tools under the abortion-drug subchapter and the Deceptive Trade Practices Act.
No committee transcript or vote record is provided, so there is no documented debate or recorded legislative sentiment in the materials supplied. Based on the bill text alone, the measure appears strongly restrictive and punitive toward abortion-inducing drug activity, reflecting a policy direction aimed at deterrence and enforcement rather than access or regulation flexibility.
The central point of contention is likely the bill’s escalation of penalties and expansion of liability for abortion-related medication providers and entities, including the move from misdemeanor to felony treatment and the $50,000-per-violation fine. Another likely dispute is the breadth of enforcement authority, especially the ability of private parties such as the father, spouse, parent, or guardian to sue, the inclusion of the Attorney General and prosecutors, and the mandatory license revocation provision for physicians. Supporters would likely frame these provisions as necessary enforcement and patient protection measures, while opponents would likely view them as punitive, expansive, and likely to chill medical practice.